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Alzheimer’s disease-like APP processing in
wild-type mice identifies synaptic defects
as initial steps of disease progression
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Abstract
Background: Alzheimer’s disease (AD) is the most frequent form of dementia in the elderly and no effective
treatment is currently available. The mechanisms triggering AD onset and progression are still imperfectly dissected.
We aimed at deciphering the modifications occurring in vivo during the very early stages of AD, before the
development of amyloid deposits, neurofibrillary tangles, neuronal death and inflammation. Most current AD
models based on Amyloid Precursor Protein (APP) overproduction beginning from in utero, to rapidly reproduce
the histological and behavioral features of the disease within a few months, are not appropriate to study the early
steps of AD development. As a means to mimic in vivo amyloid APP processing closer to the human situation in
AD, we used an adeno-associated virus (AAV)-based transfer of human mutant APP and Presenilin 1 (PS1) genes to
the hippocampi of two-month-old C57Bl/6 J mice to express human APP, without significant overexpression and to
specifically induce its amyloid processing.
Results: The human APP, βCTF and Aβ42/40 ratio were similar to those in hippocampal tissues from AD patients.
Three months after injection the murine Tau protein was hyperphosphorylated and rapid synaptic failure occurred
characterized by decreased levels of both PSD-95 and metabolites related to neuromodulation, on proton magnetic
resonance spectroscopy (1H-MRS). Astrocytic GLT-1 transporter levels were lower and the tonic glutamatergic
current was stronger on electrophysiological recordings of CA1 hippocampal region, revealing the overstimulation
of extrasynaptic N-methyl D-aspartate receptor (NMDAR) which precedes the loss of long-term potentiation (LTP).
These modifications were associated with early behavioral impairments in the Open-field, Y-maze and Morris Mater
Maze tasks.
Conclusions: Altogether, this demonstrates that an AD-like APP processing, yielding to levels of APP, βCTF and
Aβ42/Aβ40 ratio similar to those observed in AD patients, are sufficient to rapidly trigger early steps of the
amyloidogenic and Tau pathways in vivo. With this strategy, we identified a sequence of early events likely to
account for disease onset and described a model that may facilitate efforts to decipher the factors triggering AD
and to evaluate early neuroprotective strategies.
Keywords: Alzheimer’s disease early stages, Aβ ratio, Human samples, Animal model, Extrasynaptic NMDAR,
Synaptic failure
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Background
Alzheimer’s disease (AD) is characterized by amyloid de-
posits, intracellular neurofibrillary tangles, neuronal loss
and a progressive decline in cognitive function [1, 2].
Much progress has been made towards understanding the
physiopathology of the disease, mostly through studies of
transgenic mice designed to reproduce, as closely as pos-
sible, the histological and behavioral features of AD [3, 4].
AD is multifactorial, but the abnormal processing of
Amyloid Precursor Protein (APP) is a key element in its
development [5]. The physiological functions of APP are
unclear, but it has been shown to play crucial roles in
spine density, morphology and plasticity [6]. The injec-
tion of anti-APP antibodies into the rat brain is known
to induce behavioral impairments [7, 8]. Furthermore,
APP knockout mice have very low levels of dendritic
complexity [9]. Altogether, this suggests that APP has an
important physiological role associated with synaptic
plasticity as well as trophic properties. Overexpression
of wild-type (WT) APP and various mutant forms has
been used as a means to model AD in many transgenic
mouse lines [10, 11]. In most of these transgenic strains,
the significant increase in APP production beginning in
utero may trigger consequences that are not likely mim-
icking the biochemical deficit observed in AD. Interest-
ingly, Saito and coworkers recently described a new APP
knock-in model without APP overproduction [12]. This
model reproduces the cognitive deficits and amyloid pla-
ques of AD, but unfortunately does not provide informa-
tion about changes occurring early in the development
of the pathology.
If the role of amyloid component is crucial, the role of
amyloid plaque deposition in disease development is
currently a matter of debate [13]. The presence of pla-
ques is a diagnostic criterion for AD, but several studies
have suggested that the accumulation of amyloid de-
posits may have a protective function [14]. Moreover, an
absence of plaque has been reported in patients with fa-
milial AD and mutant forms of APP [15], whereas abun-
dant Aβ plaques have been found in brain samples from
elderly patients without clinical dementia [16–19]. Pla-
ques appear many years after disease onset and they can-
not, therefore, be responsible for the early events in AD
development [20]. By contrast, soluble Aβ may play an
important role in the synaptic and cognitive impair-
ments observed in the early stages of AD [21]. The use
of transgenic models displaying higher levels of APP and
cleavage products compared to the human situation and
inducing artificial phenotypes in few months is therefore
likely to be inappropriate for studies of the initial phases
of AD. The levels of Aβ produced in these models are
much higher than those observed in patients and may
have toxic effects unrelated to the early phases of AD. In
addition, the negative outcomes of recent clinical trials
have fueled debate about the validity of overexpression
models. Indeed, most of the therapeutic strategies previ-
ously tried and largely unsuccessful, have been tested in
such transgenic models. There is a growing body of evi-
dence suggesting that amyloid plaques and tangles occur
late in disease progression. Therefore, the development of
pertinent protective or disease-modifying therapeutic
strategies based on the decrease of these markers does not
seem to fit well [22, 23]. These compelling observations
demonstrate the need to develop new alternative models
of AD more closely mimicking the human disease and in
particular the early events in its development.
The present study is an attempt at developing such an
alternative model involving the production, in vivo, in the
mouse hippocampus, of moderate levels of amyloid deriv-
atives, resembling as closely as possible the pattern of ex-
pression observed in the hippocampus of human AD
patients to study the consequences of initial amyloid path-
way engagement. We used this modelling strategy to
analyze the events potentially contributing to AD develop-
ment before the appearance of late hallmarks of the dis-
ease, such as amyloid deposits, neurofibrillary tangles and
neuronal death. The injection of AAV vectors carrying
mutated forms of human APP and PS1 into the mouse
hippocampus led to the stable production [24, 25] of APP,
βCTF and Aβ peptides, at levels similar to those observed
in the hippocampus from AD patients and significantly
lower than those present in the hippocampus of APP/
PS1ΔE9 transgenic mice. The data generated demonstrate
the importance of the Aβ42/Aβ40 ratio, which has already
been identified as a relevant biomarker in AD patients
[26], together with early changes in synaptic functions,
Tau phosphorylation and cognitive deficits. These modifi-
cations were observed in the absence of plaque formation,
or any sign of inflammation, atrophy and/or neuronal
death. They were nevertheless capable of inducing
cellular changes, such as the abnormal activation of
extrasynaptic NMDARs and a decrease in the levels
of neuromodulation-associated metabolites, causing
memory impairment. These results suggest that APP
processing in a limited number of neurons, as re-
cently observed in sporadic forms of AD [27], may be
sufficient to trigger an impairment of hippocampal-
dependent behavior.
Results
Injections of the AAV-APP and AAV-PS1 vectors lead to
APP and PS1 transgenes expression in the hippocampus
of wild-type mice, from one month after injection
We generated AAV vectors encoding human mutant
full-length PS1M146L and human mutant APPSL. These
vectors were injected bilaterally into the stratum lacuno-
sum of the hippocampus of eight-week-old C57BL/6 J
mice. We used the AAVrh.10 capsid, which is known to
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transduce the central nervous system and the hippocam-
pus efficiently [28]. We studied four groups of animals:
non-injected wild-type mice (non-injected WT mice),
mice receiving the AAV-CAG-PS1M146L vector (AAV-
PS1 mice), mice receiving the AAV-CAG-APPSL vector
(AAV-APP mice) and mice receiving a co-injection of
both vectors (AAV-APP/PS1 mice, Fig. 1a). To monitor
vector-mediated APP and PS1 expression, mice were
killed one month after injection. Western blot analysis
of whole hippocampus revealed comparable full-length
PS1 (PS1 FL) expression in the four groups, despite a
trend to increase in AAV-PS1 and AVV-APP/PS1 mice
(Fig. 1b and c). Interestingly, 30 kDa PS1 N-terminal
fragment (PS1 NTF) was mainly detectable in AAV-PS1
and AAV-APP/PS1 hippocampi (Fig. 1b and d). This PS1
NTF production confirms the endoproteolysis of ex-
ogenous PS1 FL which is essential for the formation of
the PS1 active site responsible for the formation the Aβ
species [29]. AAV-APP and AAV-APP/PS1 mice showed
exogenous human APP expression with higher amount
in the AAV-APP mice hippocampi (6E10 antibody,
Fig. 1b and e). By contrast, the total amount of APP (ex-
ogenous human + endogenous murine forms, APP C-ter
antibody) did not differ significantly between non-
injected WT, AAV-PS1 and AAV-APP/PS1 mice (Fig. 1b
and f). Immunohistochemical analyses of hippocampal
sections using an APP C-ter antibody revealed a notice-
able overexpression of APP only in the AAV-APP mice
and observed in the CA2 layer and in the subiculum
subfield of the hippocampus (Fig. 1g). Consistent with
the result on total APP expression (see Fig. 1f ), the hu-
man APP expression in the AAV-APP/PS1 group (see
Fig. 1e) was not sufficient to be detected by immunohis-
tochemistry. Double-immunostaining with the NeuN
antibody confirmed that essentially neurons were trans-
duced by the vectors. No transduction of astrocytes or
microglia was observed (data not shown). Analysis of
serial anteroposterior coronal sections demonstrated
widespread APP C-ter immunoreactivity in the hippo-
campus from -0.94 mm to -2.46 mm from the Bregma
(Fig. 1h-l). Subcellular clustering of human APP was ob-
served in transduced neurons (Fig. 1m). By contrast,
staining with the 4G8 antibody, which detects both APP
full length and Aβ, yielded a diffuse signal from the
intracellular compartment and extracellular medium,
suggesting that APP or its cleavage products like Aβ spe-
cies, may diffuse out of the transduced cells into the ad-
jacent parenchymal space (Fig. 1m).
Amyloidogenic processing of human APP in AAV-APP/PS1
mice promotes Tau phosphorylation, 3 months after
injection
To confirm the production of human Aβ, we evaluated
the processing of human APP in non-injected WT, AAV-
PS1, AAV-APP and AAV-APP/PS1 mice three months
after vector injection. βCTF, the first cleavage product of
the amyloidogenic pathway [30] was quantified by ELISA
(Fig. 2a). AAV-APP mice produced larger amounts of hu-
man βCTF than non-injected WT, AAV-PS1 and also
AAV-APP/PS1 mice (p = 0.045). We then quantified the
production of the sAPPβ fragment, which is also produced
by Bace1 activity, and found a linear relationship between
the levels of this fragment and βCTF production (Fig. 2b;
Spearman correlation test, r2 = 0.85, p = 0.0034). Next, we
evaluated Bace1 levels and activity. We did not observe
any modification between the four groups (data not
shown). As observed for the human βCTF, no human
Aβ42 was detected in non-injected WT and AAV-PS1
mice. Interestingly, larger amounts of Aβ42 were detected
in AAV-APP/PS1 mice than in AAV-APP mice (Fig. 2c),
and there was an inverse correlation between βCTF and
Aβ42 levels between AAV-APP and AAV-APP/PS1 mice
(Fig. 2d; Spearman correlation test, r2 = 0.65, p = 0.03).
These results suggest that, in AAV-APP/PS1 mice, human
βCTF is cleaved by the exogenous PS1 to produce larger
amounts of Aβ42 peptide. This production/diffusion was
restricted to the hippocampus and was not observe in cor-
tical areas (data not shown). We then investigated the ra-
tios of the amounts of the various Aβ species. Aβ42/Aβ40
and Aβ42/Aβ38 ratios were significantly higher in AAV-
APP/PS1 compared to AAV-APP mice (Fig. 2e and f; p <
0.001). Despite production of both Aβ42 and Aβ40, no
amyloid deposit was detected in the cortex and hippocam-
pus of AAV-PS1, AAV-APP or AAV-APP/PS1 mice by
staining with either Thioflavin S, Congo red or other
amyloid antibodies (data not shown). We also carried out
immunostaining for GFAP and Iba1 to analyze the poten-
tial astrocytic (GFAP) and microglial (Iba1) responses in-
duced by amyloid APP processing. No recruitment of
astrocytes or microglia, or change in cellular morphology
suggestive of activation process was observed three
months after injection (data not shown). We then investi-
gated the potential impact of the amyloidogenic pathway
on phosphorylation of the endogenous Tau protein. ELISA
(AT270, Thr181) demonstrated significant increase in Tau
phosphorylation in AAV-APP/PS1 mice three months
after injection compared to non-injected WT, AAV-PS1
and AAV-APP mice (Fig. 2g; p = 0.04). By contrast, no
modification of total Tau amount was observed in these
four groups suggesting a modification of Tau kinase/phos-
phatase balance in AAV-APP/PS1 mice (Fig. 2h).
Similar levels of human APP and amyloid derivatives are
observed in the hippocampus of AAV-APP/PS1 mice and
AD patients
We compared the levels of APP and amyloid derivatives
in non-injected WT, AAV-PS1, AAV-APP and AAV-
APP/PS1 mice (3 months after injection i.e. in five-
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month-old mice) with those present in the hippocampus
of human controls and AD patients (five age-matched
controls + five AD Braak 6/Thal 5 patients) and in APP/
PS1ΔE9 transgenic mice [31]. Human APP content was
found to be lower in AD cases than in age-matched con-
trols, even after normalization for neuronal NeuN
Fig. 1 Stereotactic injection of AAV vectors induces the neuronal expression of human APP and PS1 in the hippocampus of C57BL/6 J mice, 1 month
after injection. C57Bl/6 J mice (all males) were injected at 8 weeks of age either with AAV-CAG-PS1M146L (AAV-PS1 mice, n = 4), AAV-CAG-APPSL
(AAV-APP mice, n = 4) or both vectors at the same doses as for the other two groups (AAV-APP/PS1 mice, n = 4). Non-injected WT mice (n = 4) were
also analyzed. Mice were killed one month later for analyses. a Upper panel: schematic representation of the four groups used. Bottom panel: coronal
diagram showing the injection site and the architecture of the mouse hippocampus. b Representative western blots showing the expression of PS1
(full length: PS1 FL and N-terminal fragment: PS1 NTF), human APP (6E10 antibody) and total APP (murine + human forms; APP C-ter antibody)
confirming transgene expression 1 month after injection. All western blots were performed on the whole hippocampus (TBS-Tx soluble fraction).
c-f Densitometric analyses of western blots showing the expression of PS1 FL (c), PS1 NTF (d), human APP (e) and total APP (f) in the four groups
hippocampi 1 month after injection. Note that despite the expression of human APP in the AAV-APP/PS1 group, no significant difference in total APP
levels was found between non-injected, AAV-PS1 and AAV-APP/PS1 groups. Bars represent means ± SEM and data were normalized with respect to
GAPDH. Statistical analysis was performed by one-way ANOVA followed by Tukey’s post-hoc test where ###, *** and $$$ denote p < 0.001 versus
non-injected WT mice, AAV-PS1 mice and AAV-APP mice respectively. ##, ** and $$ denote p < 0.01; # and * denote p < 0.05. g High magnification of
a hippocampal coronal section of each group showing neuronal layers (NeuN antibody, red) and the APP expression (APP C-ter antibody, green). Note
that the human APP expression in the AAV-APP/PS1 group (see Fig. 1e) is not sufficient to exceed a threshold detectable by immunohistochemistry.
The exogenous APP is essentially detected into two areas: the CA2 and subiculum. Scale bar represents 500 μm. h Scheme representing
antero-posterior coordinates of coronal sections depicted in (i-l). i-l Immunostaining of APP (APP C-ter antibody, green) and NeuN (red) at
different antero-posterior coordinates in AAV-APP mice coronal sections. m Magnified confocal images of an AAV-APP mouse section with
double immunofluorescence staining showing the location of APP (APP C-ter antibody, green) and the diffusion of Aβ indicated by arrow
heads (4G8 antibody, red) in the CA2 layer. Blue: DAPI. Scale bar represents 10 μm
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marker expression (p = 0.03), suggesting a higher rate of
APP processing in sporadic forms of AD (Fig. 3a and b;
Additional file 1: Figure S1). The amount of human APP
present in the hippocampus of AAV-APP/PS1 mice was
similar to that observed in the hippocampus of AD pa-
tients. By contrast, much larger amounts of human APP
were found in five-month-old APP/PS1ΔE9 mice (Fig. 3a
and b, p < 0.0001). Interestingly, total amount of APP
was not significantly modified by virus injection com-
pared to non-injected WT mice and in contrast to 5
months old APP/PS1ΔE9 who displayed a two-fold
accumulation (p = 0.0011, Fig. 3c and d). We then evalu-
ated metabolites released by the amyloidogenic pathway
into the hippocampus of mice receiving AAV injections
and compared it to those found in APP/PS1ΔE9 trans-
genic mice at different ages and human AD patients. We
used 14 and 16-month-old APP/PS1ΔE9 mice because
we detected behavioral deficits in these mice from 14-
month-old of age (internal data). βCTF levels which tend
to increase in AD patients compared to human controls,
were similar in AAV-APP/PS1 mice and in AD patients.
Interestingly, these levels were significantly lower
Fig. 2 Exogenous human APP is processed following the amyloidogenic pathway, 3 months after injection. C57Bl/6 J mice (all males) were
injected at 8 weeks of age either with AAV-CAG-PS1M146L (AAV-PS1 mice), AAV-CAG-APPSL (AAV-APP mice) or both vectors at the same doses
as for the other two groups (AAV-APP/PS1 mice, n = 7-8 mice per group). Non-injected WT mice (n = 4) were also analyzed. Mice were killed
three months later for analyses of whole hippocampi. a Comparative analysis of TBS-Tx soluble human βCTF levels by ELISA. Note that βCTF levels
follow the same pattern of expression than for the human APP in the four different groups (see Fig. 1e). Bars represent means ± SEM. Statistical
analysis was performed by one-way ANOVA with Tukey’s post-hoc test where ###, *** denote p < 0.001 versus non-injected WT and AAV-PS1
mice. #, * and $ denote p < 0.05. b Correlation between TBS-Tx soluble human βCTF and sAPPβ levels between AAV-APP and AAV-APP/PS1 mice
(n = 7). Linear regression analysis confirms the engagement in the amyloidogenic pathway. Correlation analysis was performed with Pearson’s
parametric correlation test: **p < 0.01. c Comparative analysis of TBS-Tx soluble human Aβ42 levels by MSD immunoassay showing higher levels
in AAV-APP/PS1 mice (n = 6-8 mice per group). Bars indicate means ± SEM. Statistical analysis was performed by one-way ANOVA followed by
Tukey’s post-hoc test where ###, *** denote p < 0.001 versus non-injected WT mice and AAV-PS1 mice. ## and ** denote p < 0.01. d Correlation
between TBS-Tx soluble human Aβ42 and βCTF levels between AAV-APP and AAV-APP/PS1 (n = 13). Correlation analysis was performed with
Pearson’s parametric correlation test: *p < 0.05. e-f Representation of Aβ42/40 (e) and Aβ42/38 (f) ratios determined by multiplex MSD
immunoassay (n = 4 mice per group). Bars indicate means ± SEM. Statistical analysis was performed by one-way ANOVA followed by Tukey’s
post-hoc test where $$$ denotes p < 0.001 versus AAV-APP mice. na = not applicable. g Comparative analysis of TBS-Tx soluble murine
phosphorylated Tau protein (AT270, Thr181) by ELISA. Bars indicate means ± SEM. Statistical analysis was performed by one-way ANOVA
followed by Tukey’s post-hoc test where #, * and $ denote p < 0.05 versus non-injected WT mice, AAV-PS1 mice and AAV-APP mice respectively.
h Densitometric analyses of western blots showing the expression of the total Tau protein in each group (n = 4 mice per group). Bars represent
means ± SEM and data were normalized with respect to GAPDH
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compared to both 14 and 16-month-old APP/PS1ΔE9
mice (Fig. 4a; p < 0.0001). In AAV-APP/PS1 injected
mice, a tendency towards larger amounts of Aβ42 than
in human controls was observed, but Aβ42 levels were
lower than those in patients with advanced AD and
APP/PS1ΔE9 mice at 5 months of age (Fig. 4b). Further-
more, Aβ40 levels were significantly higher in APP/
PS1ΔE9 mice compared to other groups and increased
with aging in these animals (Fig. 4c). Numerous studies
have established the ratio of Aß42 to Aß40 as an import-
ant factor in determining the toxicity of Aβ in vivo [32].
We confirmed that Aβ42/Aβ40 ratios were significantly
different between human controls and AD patients
(Fig. 4d). Interestingly, these ratios were similar between
AD patients and AAV-APP/PS1 mice, but significantly
different in APP/PS1ΔE9 mice, which had a particularly
low Aβ42/Aβ40 ratio. Together, these results indicate
that co- injection of the AAV-APP and AAV-PS1 vectors
into the hippocampus of normal mice leads to an overall
pattern of amyloid processing close to that observed in
the hippocampus of AD patients and contrasts to that of
APP/PS1ΔE9 mice. Based on results obtained during
analysis of APP processing and because AAV-PS1 mice
and non-injected WT mice appeared similar in all ana-
lyses (see Figs. 1, 2, 3 and 4), we decided to use AAV-
PS1 mice as an injected control group for further
characterizations.
NMR spectroscopy shows changes to the neurochemical
profile of the hippocampus in AAV-APP/PS1 mice
Proton magnetic resonance spectroscopy (1H-MRS) has
been shown to detect modifications in AD patients [33].
Using a 11.7 T scanner, we acquired 1H-MRS spectra
in vivo from the right and left hippocampi of AAV-PS1
and AAV-APP/PS1 mice, three months after injection, to
evaluate the early consequences of APP processing on hip-
pocampal metabolites. We determined the concentrations
of seven metabolites from spectra: GABA, glutamine
(Gln), glutamate (Glu), taurine (T), N-acetyl-aspartate +
N-acetyl-aspartyl-glutamate (tNAA), myo-inositol (Ins)
and glycerophosphocholine + phosphocholine + choline
(tCho). Macromolecules and lipids were not included in
Fig. 3 AAV-APP/PS1 mice show a production of human APP similar to AD patients, 3 months after injection. C57Bl/6 J mice (all males) were
injected at 8 weeks of age either with AAV-CAG-PS1M146L (AAV-PS1 mice, n = 4), AAV-CAG-APPSL (AAV-APP mice, n = 4) or both vectors at the
same doses as for the other two groups (AAV-APP/PS1 mice, n = 4). Non-injected WT mice (n = 4) and transgenic APP/PS1ΔE9 mice were also
used and all animals were killed at 5 months of age. Human samples were obtained from late-onset AD cases (Braak 6, Thal 5) and age-matched
controls. The hippocampus was the structure analyzed for all samples. a Representative western blot of human APP (6E10 antibody) between
AAV injected mice (n = 3 per group), human samples (n = 5 per group) and transgenic APP/PS1ΔE9 mice (n = 3). b Densitometric analyses of the
antibody immunoreactivity shown in panel (a). Bars represent means ± SEM and data were normalized with respect to GAPDH. Statistical
analysis was performed by one-way ANOVA with Tukey’s post-hoc test: ***p < 0.001. Note that AAV-APP/PS1 mice and human AD cases have
similar levels. c Representative western blot of total APP (APP C-ter antibody) between non-injected WT, AAV injected and APP/PS1ΔE9 mice.
d Densitometric analyses of the antibody immunoreactivity shown in panel c. Bars represent means ± SEM and data were normalized with
respect to GAPDH. Statistical analysis was performed by one-way ANOVA with Tukey’s post-hoc test: **p < 0.01
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the study and the values obtained were expressed as ratios
relative to creatine + phosphocreatine (tCr) (Fig. 5a). A
two-way Anova with repeated measure revealed a group
effect (p = 0.04). The concentration values obtained were
generally lower in AAV-APP/PS1 than in AAV-PS1 mice,
in absence of significant individual difference for each me-
tabolite (Group x Metabolite interaction effect (p = 0.13)).
Among studied metabolites, levels of metabolites related
to neuromodulation (GABA, Gln, Glu, T and tNAA) were
globally lower in AAV-APP-PS1 mice (Fig. 5b, group ef-
fect: p = 0.002). By contrast, metabolites not associated
with neuromodulation (Ins, tCho) were not affected by
co-injection of the AAV-APP and AAV-PS1 vectors. These
results suggest that there is a decrease in the global pool
of metabolites involved in neurotransmission processes in
AAV-APP-PS1 mice. They also rule out the possibility of a
single metabolite being entirely responsible for changes, at
this stage and in this model. In this way, the absence of in-
creased concentration of glutamate excluded glutamate
induced excitotoxicity.
AAV-APP/PS1 mice present early extrasynaptic deficits
A loss of synaptic contacts in the hippocampus is one of
the major early neuropathological findings in AD pa-
tients [34]. Moreover, deficiencies in glutamate transport
have been shown to be associated with AD [35]. We
assessed the functionality of glutamatergic synapses by
electrophysiological analyses on hippocampal slices. The
long-term potentiation (LTP) of glutamate synaptic
transmission was first evaluated in mice three months
Fig. 4 AAV-APP/PS1 mice show a production of amyloid derivatives similar to AD patients, 3 months after injection. C57Bl/6 J mice (all males)
were injected at 8 weeks of age either with AAV-CAG-PS1M146L (AAV-PS1 mice, n = 4), AAV-CAG-APPSL (AAV-APP mice, n = 4) or both vectors at
the same doses as for the other two groups (AAV-APP/PS1 mice, n = 4). Non-injected WT mice (n = 4) and transgenic APP/PS1ΔE9 mice at 5
(n = 3), 14 (n = 8) and 16 (n = 8) months of age were also used. Human samples were obtained from late-onset AD cases (Braak 6, Thal 5) and
age-matched controls. The hippocampus was the structure analyzed for all samples. a Comparative analysis of TBS-Tx soluble human βCTF levels
by ELISA. Statistical analysis was performed by one-way ANOVA with Tukey’s post-hoc test: ***p < 0.001. A logarithmic scale was used. Note that
AAV-APP/PS1 mice and human AD cases have similar levels. b-c Quantification (6E10 based MSD immunoassay detecting human Aβ species) of
TBS-Tx soluble human Aβ42 (b) and Aβ40 (c). Statistical analysis was performed by one-way ANOVA with Tukey’s post-hoc test: ***p < 0.001,
**p < 0.01. Note that AAV-APP/PS1 injected mice show higher levels of Aβ42 compared to human controls and reduced levels compared to late
stage human cases. d Representation of the Aβ42/40 ratio. Note that no significant difference was detectable between AAV-APP/PS1 mice and
human AD cases
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Fig. 5 (See legend on next page.)
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after injection. A trend towards a decrease in LTP ex-
pression following high-frequency stimulation but not
theta burst stimulation was found to be linked to the co-
expression of APPSL and PS1M146L (Fig. 5c; p = 0.11).
Beside, we recorded the tonic current generated in CA1
pyramidal cells by the ambient levels of glutamate acting
on extrasynaptic NMDA receptors (NMDAR). The amp-
litude of the tonic current was significantly greater in
the AAV-APP/PS1 mice and characterized by a signifi-
cant dispersion of current amplitude suggesting greater
disorganization of the synapse in this population than in
the more homogeneous AAV-PS1 or AAV-APP mouse
groups (Fig. 5d). Indeed, no difference was observed be-
tween the AAV-PS1 and AAV-APP groups (Additional
file 2: Figure S2). Synaptic dysfunction occurs early in
AD [34] and brains of AD patients have been shown to
contain abnormally low levels of synaptic proteins [36].
We compared the levels of the PSD-95 and synaptophy-
sin synaptic markers in the hippocampus of AAV-PS1
and AAV-APP/PS1 mice. PSD-95 levels were signifi-
cantly lower in AAV-APP/PS1 than AAV-PS1 mice (p =
0.007), while synaptophysin was not modified (Fig. 5e
and f). Next we investigated the contribution of extrasy-
naptic glutamate receptor uptake further, by assessing
the expression of two astrocytic glutamate transporters,
GLT-1 and GLAST. AAV-APP/PS1 mice were found to
have significantly lower levels of GLT-1 (p = 0.003), with
no difference in GLAST levels (Fig. 5g and h).
AAV-APP/PS1 mice develop early cognitive deficits
Most transgenic mouse models of AD reproduce cogni-
tive impairments relevant to the human disease. In most
of these models, progressive deficits are associated with
excessive Aβ production at an advanced age [3]. We
evaluated weather moderate amyloid production in
AAV-APP-PS1 mice could be associated with early
cognitive dysfunctions. We used AAV-PS1 as control
group since previous studies demonstrated that mutant
PS1 overexpression in mouse hippocampus did not in-
duce cognitive abnormalities in Morris Water Maze [37]
nor in Y-Maze tasks [38], and APP processing profile
was similar in WT animals and AAV-PS1 animals (see
Figs. 1, 2, 3 and 4). In the Open-field task a decreased
distance travelled across time suggests habituation to the
novel environment as classically described [39]. Distance
travelled during task was similar between AAV-PS1 and
AAV-APP/PS1 mice confirming no motor abnormality
in our experimental AD mouse model (Fig. 6a). Interest-
ingly, AAV-APP/PS1 mice displayed a much higher per-
iphery/center ratio than AAV-PS1 mice. This difference
in behavior may either reflect changes in emotional be-
havior when faced to a new environment or an increase
in anxiety (Fig. 6b; p = 0.02). Similarly to Open-field,
both groups showed habituation during the Ymaze task,
confirmed by a decrease of distance travelled across time
(Fig. 6c). No motor impairment was observed in AAV-
PS1 and AAV-APP/PS1 mice. Furthermore, a trend
towards short term memory impairment was observed
in AAV-APP/PS1 mice that spent less time than
AAV-PS1 mice exploring the new arm of the maze
(Fig. 6d; p = 0.08). Finally, we assessed spatial learn-
ing and memory, using the Morris Water Maze task.
The travelled distance to find the hidden platform
was not different between both groups over time
(Fig. 6e) with no difference during this learning phase
(data not shown). Interestingly, AAV-PS1 mice spent
longer in the target quadrant than AAV-APP/PS1
mice (Fig. 5f and g) in both the four-hour (p = 0.054)
and the 72-h (p = 0.0085) probe tests indicating an
alteration in memory retention in AAV-APP/PS1
mice. Thus, AAV-PS1 mice displayed a spatial bias in
the target quadrant during both the 4-h (target
(See figure on previous page.)
Fig. 5 AAV-APP/PS1 mice present synaptic defects, 3 months after injection. C57Bl/6 J mice (all males) were injected at 8 weeks of age either
with AAV-CAG-PS1M146L (AAV-PS1 mice used as an injected control group, n = 10) or AAV-CAG-APPSL + AAV-CAG-PS1M146L (AAV-APP/PS1
mice, n = 10). Mice were used for in-vivo (a-b) and ex-vivo (c-d) recording three months later. a Top panel: localization of the spectroscopic
volume of 7.2 mm x 2 mm x 2.6 mm encompassing both. Hippocampi of each mouse. Bottom panel: representative 1H-MR spectrum acquired
from the hippocampus of a mouse 3 months after injection. b Concentrations of seven metabolites were determined from spectra: GABA, Gln,
Glu, T, tNAA, Ins and tCho. Macromolecules and lipids were not included in the study and the values obtained were expressed as ratios relative
to tCr (n = 10-11 per group). Bars represent means ± SEM. Statistical analysis was performed by two-way ANOVA with experimental group and
metabolites as effects. Note that metabolite levels were significantly lower in AAV-APP/PS1 mice (experimental group effect: p = 0.04). A selective
analysis of metabolites linked to neuromodulation and precursors (GABA, Gln, Glu, T, tNAA) increased the significance of the difference between
both groups (experimental group effect: p = 0.002). c Long-term potentiation (LTP) over 75 min induced by high-frequency stimulation. The inset
graphs represent for each group an example of unit field excitatory postsynaptic potentials (fEPSP) before (black line) and after (gray line) LTP
induction. The inset histogram shows average potentiation. Bars represent means ± SEM (n = 15-16 slices from n = 10 mice per group). Statistical
analysis was performed with Student’s t-test. d Scatter diagram showing the tonic glutamatergic current recorded at a holding potential of +40
mV (whole cell patch-clamp of CA1 pyramidal cells, n = 11-19/group from n = 10 mice per group). Normal response was characterized in a range
comprised between AAV-PS1 mean +/- 2SD. Analysis of AAV-APP/PS1 profile revealed a decrease of number of neurons with normal response
(Chi2 test: p = 0.003) in association with an increase of neurons with an high level of Tonic glutamatergic current (Chi2 test: p = 0.011) suggesting
this current was stronger in the AAV-APP/PS1 group. e-h Western blot analysis of PSD-95, Synaptophysin, GLT-1 and GLAST. Bars represent means
± SEM and data were normalized with respect to GAPDH. Student’s t-test was used for statistical analysis: *p < 0.05
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quadrant TQ vs. mean of other quadrants OQ; p = 0.031)
and 72-h (TQ vs. OQ; p = 0.023) probe tests, confirming
their preserved spatial memory. By contrast, AAV-APP/PS1
mice did not spend more time in the target quadrant in
either the four-hour (TQ vs. OQ; p = 0.06) or the 72-h (TQ
vs. OQ; p = 0.69) probe trial, confirming an absence of effi-
cient memorization of platform position. These data suggest
that co-injection of both vectors triggers detectable memory
impairment as soon as three months after injection.
Discussion
Alzheimer’s disease (AD) is a complex condition. To im-
prove our understanding of the physiopathology of the
disease and design new therapeutic strategies, it is cru-
cial to get access to the initial phases of its development.
We aimed at recapitulating in vivo key features that are
suspected to account for triggering AD, more specifically
an increased Aβ42/Aβ40 ratio, while avoiding major
APP overexpression. The importance of the Aβ ratio in
the disease onset above their absolute levels has been
already proposed [40] and the absence of APP overpro-
duction is increasingly being recognized as an important
factor to take into account when modeling AD [12]. To-
wards this goal, we developed an alternative approach to
existing models, involving a single co-administration of
two AAV vectors encoding human mutated APP (APPsl)
and PS1 (PS1M146L) in adult wild-type mice hippocampi.
Transgenic mice expressing WT form of the 695-
amino acid isoform of APP do not develop AD-like
phenotype nor behavioral impairment [41, 42] in con-
trast to APP751 transgenic mice which have strong
learning deficits at 12 months of age [11]. Therefore, the
APP751 isoform seems more interesting to trigger an
AD-like phenotype. In order to specifically enhance
amyloidogenic APP processing, we decided to express
the APP751 isoform including the Swedish and London
mutations [43]. We simultaneously expressed PS1 with
the M146L mutation to increase the specificity of the
42-specific γ-secretase cleavage [44]. Thus, the co-
expression of PS1 (PS1M146L) with APP751SL resulted
in an increased production of Aβ with an Aβ42/Aβ40 ra-
tio similar to the one observed in AD patients. Interest-
ingly, increase of APP cleavage products was not
associated with amyloid deposition, neurofibrillary tan-
gles and neuronal loss.
AAV-APP/PS1 mice display cognitive impairment as
early as three months post-injection. These memory de-
ficiencies reflect a global impairment of neuronal activ-
ity, as suggested by 1H-MRS, showing the levels of
metabolites related to neurotransmission expressed in
the hippocampus globally reduced. These result high-
lights that there is an early response of neurons to the
APP processing affecting their functionality.
To get further insight in the understanding of this neur-
onal dysfunction, we used electrophysiological recordings
on the CA1 layer to characterize synaptic consequences of
moderate soluble Aβ42 production. We observed an en-
hancement of the tonic glutamatergic current generated
in CA1 pyramidal cells of AAV-APP/PS1 mice. Two types
of N-methyl D-aspartate receptors (NMDARs) have been
described (synaptic and extrasynaptic), the tonic current
resulting mostly from the activation of the extrasynaptic
subgroup, stimulated by ambient glutamate present out-
side the synaptic cleft [45, 46]. As we did not observe an
increase of glutamate synthesis by 1H-MRS, the higher
tonic current observed in AAV-APP/PS1 mice may reflect
the accumulation of glutamate in the extrasynaptic space.
There are two possible explanations for this possible accu-
mulation. First, lower levels of glutamate transporters,
such as GLT-1, may result in weaker levels of glutamate
uptake by astrocytes [35]. Second, lower levels of scaffold-
ing proteins, such as PSD-95, may lead to the internaliza-
tion of synaptic NMDARs, resulting in the preferential
activation of extrasynaptic ones [47]. AAV-APP/PS1 mice
display these features since they express significantly lower
levels of GLT-1 and PSD-95. No decrease of GLAST, the
second most important glutamate transporter, was
(See figure on previous page.)
Fig. 6 AAV-APP/PS1 mice present memory impairments, 3 months after injection. C57Bl/6 J mice (all males) were injected at 8 weeks of age
either with AAV-CAG-PS1M146L (AAV-PS1 mice used as an injected control group, n = 8) or AAV-CAG-APPSL + AAV-CAG-PS1M146L (AAV-APP/
PS1 mice, n = 8) and behavioral analyses were performed three months later. a Open-field assay. Travelled distance during the Open-field task
showing no significant difference between both groups. b Left panel: time in periphery/time in center ratio showing a change in emotional
behavior when faced to a new environment in the AAV-APP/PS1 group (n = 7-8 mice per group). Bars represent means ± SEM. Statistical analysis
was performed with Student’s t-test: *p < 0.05. Right panel: group occupancy plots for visualizing the areas in which the animals spent the most
time during the test. c Y-maze assay. Travelled distance during the Y-Maze task showing no significant difference between both groups during
the test session. d Left panel: percentage of distance in the new arm showing that AAV-APP/PS1 mice spent less time in the new arm than the
other groups (p = 0.08; n = 7-8 mice per groups). Bars represent means ± SEM. Statistical analysis was performed with Student’s t-test. Right panel:
group occupancy plots for visualizing the areas in which the animals spent the most time during the test. The arm circled in red is the new arm.
e Morris Water Maze assay. Travelled distance during the Morris Water Maze task showing no significant difference between both groups during
the five training days. f-g Probe trial performance at 4 h (f) and 72 h (g) after the last training session. TQ = target quadrant that housed the
platform during the training sessions. OQ = mean of distance covered in the other three quadrants. Note that AAV-APP/PS1 mice were impaired
in comparison to AAV-PS1 mice confirmed by no preference for the trained target quadrant. Bars represent means ± SEM. A two way ANOVA
was used with experimental group and quadrant as main effects: *p < 0.05, **p < 0.01
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observed which might suggest that GLAST expression
could be decreased later in the course of the disease [48].
This hypothesis is not surprising, in light of published data
about GLT-1 and PSD-95 dysfunctions, which may play
an important role in synaptic dysfunction and, thus, in the
pathogenesis of AD [49, 50]. To our knowledge, we show
for the first time that an impairment of the extrasynaptic
compartment could precede sustained alterations of the
synaptic compartment associated with LTP deficits, during
the early stage of AD progression. We also showed that a
subtle loss of neuronal integrity in the hippocampus is suf-
ficient to trigger deleterious effects before actual neuronal
death occurs. Despite diffusion properties of Aβ42 [51],
no amyloid peptide have been detected outside the hippo-
campus excluding an Aβ42 direct effect far from its hip-
pocampal production area. By contrast, Aβ altered
hippocampus functions could lead to a less efficient com-
munication between hippocampal neurons and connected
structures especially cortex and amygdala. This network
dysfunction could be responsible of cognitive modifica-
tions especially during memory formation [52, 53] or
emotional behaviors [54].
In addition to these consequences, AAV-APP/PS1
mice displayed higher levels of Tau phosphorylation
(thr181, AT270 antibody) compared to the other groups.
It has been reported that soluble Aβ and extrasynaptic
NMDAR activation contribute to Tau protein phosphor-
ylation [55, 56]. Our results are consistent with these
previous reports. The pattern of Tau phosphorylation
was shown to be correlated with the multiple steps of
neurofibrillary tangle development [57]. Thr181 immu-
noreactivity is detected earlier than thr212/Ser214
(AT100 antibody) or ser199/ser202/thr205 (AT8 anti-
body) immunoreactivity. We could not detect some AT8
or AT100 positive cells (data not shown), suggesting that
the modifications observed in AAV-APP/PS1 mice might
be compared to early phases of AD in humans. These
data suggest that the moderate AD-like APP processing
engagement observed in AAV-APP/PS1 mice is suffi-
cient to trigger the Tau pathway engagement.
A particular feature in our experimental strategy is the
localized production of human APP and its cleavage
products. Contrasting with the ubiquitous overproduc-
tion of human APP in mouse transgenic lines, injection
of AAV-APP and AAV-PS1 vectors in the stratum lacu-
nosum moleculare region, leads to the transduction of
neurons in restricted regions of the hippocampus (CA2
and the subiculum). Interestingly, this pattern of expres-
sion may mimic the genomic mosaicism recently de-
scribed in AD, in which an increase in copy number was
observed for the APP gene in a limited number of neu-
rons, in sporadic forms of AD [27]. The presence of rare
neurons with APP amplification may be sufficient to
trigger a dysregulation of APP processing with aging.
Our findings also point to this direction. The second
particular feature in our experimental design is the co-
injection of the PS1 vector. Indeed, we demonstrated
that AAV-APP injection alone was not sufficient to in-
duce hippocampal alteration. Thus, despite the produc-
tion of βCTF, Aβ40 and Aβ42 in AAV-APP mouse
hippocampus, no change in the levels of phosphorylated
Tau, PSD-95, GLT-1 or tonic current were observed,
compared to the AAV-APP/PS1 group. There are two
possible reasons for this difference between the AAV-
APP and AAV-APP/PS1 groups. First, APP acts as a
trophic factor [58] and an increase in the levels of this
molecule may increase neuron viability [59], countering
Aβ toxicity. Second, the Aβ42/Aβ40 ratios in the AAV-
APP/PS1 group were highly similar to those found in
AD patients and different from those of the AAV-APP
group or human controls.
Our data raise several questions. This configuration,
with no plaque nor tangle and with levels of APP cleav-
age products close to the human hippocampal condition,
is sufficient to induce cognitive impairment three
months after injection. It takes about 13 months to ob-
tain an equivalent defect in APP/PS1ΔE9 mice [60]. This
delayed cognitive impairment may result from the
trophic roles of APP and the low Aβ42/Aβ40 ratio ob-
served in 5- to 16-month-old APP/PS1ΔE9 mice. These
findings confirm the greater importance of the Aβ ratio
rather than the absolute amounts of Aβ42 and Aβ40
[40] to induce synaptic and extrasynaptic impairments.
Finally, neurons may become brittle, leading to cognitive
impairments, with defects in emotional behavior and
long-term memory.
Conclusions
This study reports the development of a novel mouse
model focusing on the early consequences of the amyl-
oid processing of APP with similarities to human AD
cases. Our results support the importance of the Aβ42/
Aβ40 ratio to trigger initial neuronal dysfunctions
in vivo. All mechanisms described here are consistent
with memory impairments in the earliest stages of the
clinical disease beginning with subtle changes in the effi-
cacy of hippocampal synapses, before amyloid deposition
and neuronal loss. It appears that minimal dysregulation
of amyloidogenic pathway is sufficient to set up synaptic,
and notably extrasynaptic dysfunctions, potential first
step towards the full AD phenotype. Using animal
models closely mimicking the human disease in terms of
APP and APP cleavage products and focusing on early
stages of AD development may increase our understand-
ing of disease onset. This model may ultimately make it
possible to identify early biomarkers of AD while evalu-
ating relevant neuroprotective therapeutic strategies.
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Methods
Plasmid design and vector production
We used a double-mutant human APP751 cDNA con-
taining the Swedish and London mutations (codon opti-
mized and containing a Kozak sequence; GeneArt, Life
Technologies, Saint Aubin, France), and a human PS1
cDNA containing the M146L mutation (pENTR4-PS1-
S182M146L). The APPSL and PS1M146L sequences
were cloned in an AAV2 plasmid with CAG promoter to
generate the AAV2-CAG-APPSL or -CAG-PS1M146L.
AAV vectors were produced as previously described
[61], except that the AAV packaging plasmid was re-
placed with a plasmid construct containing the rep gene
of AAV2 and the cap gene of AAVrh10.
Human brain samples
Postmortem samples were obtained from brains col-
lected as part of the Brain Donation Program of the
GIE-Neuro-CEB Brain Bank. Autopsies were carried out
by accredited pathologists, after informed consent had
been obtained from the relatives, in accordance with
French Bioethics laws. Five hippocampal samples from
five patients with sporadic forms of AD (male and fe-
male; Braak 6 Thal 5; aged between 69 and 89 years,
with a postmortem interval (PMI) of 30 to 59 h) and five
hippocampus samples from five age-matched control
subjects (male and female, aged between 69 and 92
years, PMI of 6 to 63 h) were used in this study.
Animals
We used 90 male C57Bl/6 J mice (eight-week-old; SARL
JanvierLabs, Le Genest Saint Isle, France) and 19 male
APP/PS1ΔE9 mice [31]. All experiments were conducted
in accordance with ethical standards and French and
European regulations (Directive 2010/63/EU).
Stereotactic injections of AAVs
Mice were anesthetized by an intraperitoneal injection
of ketamine/xylazine (0.1/0.05 g/kg body weight) and
placed in a stereotactic frame (Stoelting, Wood Dale, IL,
USA). Stereotactic intracerebral injections of AAVs into
the hippocampi of both hemispheres were performed,
using the following coordinates: antero-posterior: -2
mm, lateral: ± 1 mm, ventral: -2 mm relative to bregma.
We injected 2 μl of viral preparation into each site (5 x
108 vg/site and 109 vg/site for AAV-PS1 and AAV-APP
vectors, respectively) at a rate of 0.2 μl/min. Four groups
were designed, a non-injected wild-type (non-injected
WT mice) and three injected groups: AAV-CAG-
PS1M146L (AAV-PS1 mice), AAV-CAG-APPSL (AAV-
APP mice), AVV-CAG-APPSL + AAV10-CAG-PS1M146L
(AAV-APP/PS1 mice).
Tissue collection and sample preparation
Mice were anesthetized with ketamine/xylazine and
transcardially perfused with 20 ml ice-cold phosphate-
buffered saline (PBS). One hemisphere was post-fixed by
incubation for 48 h in 4 % PFA, cryoprotected in 30 %
sucrose in PBS and cut into 40 μm sections with a freez-
ing microtome (Leica) for histological analyses. The
contralateral hemisphere was dissected for isolation of
the hippocampus and cortex. Samples were homoge-
nized in a lysis buffer (150 mM NaCl and 1 % Triton in
Tris-buffered saline, referenced as TBS-Tx) containing
phosphatase (Pierce) and protease (Roche) inhibitors
and centrifuged for 20 min at 15000 g. The same pro-
cedure was applied to human samples (GIE NeuroCEB
Brain Bank).
ELISA
The Aβ extracted was quantified with the MSD Human
Aβ42 V-PLEX Kit and the triplex Aβ Peptide Panel 1
(6E10) V-PLEX Kit (Meso Scale Diagnostics, Rockville,
USA). βCTF was determined with the IBL Human APP
βCTF Assay Kit (IBL International GmbH, Hamburg,
Germany). Hyperphosphorylated Tau was determined
with the Innogenetics Phospho-Tau 181P kit (Fujirebio
Europe, Ghent, Belgium). sAPPβ was determined with
the MSD sAPPalpha/sAPPbeta Kit. ELISA was per-
formed according to the kit manufacturer’s instructions
in each case.
Western blotting
Equal amounts of protein (30 μg) were separated by
electrophoresis in NuPAGE Bis-Tris Gels (Life Tech-
nologies) and transferred to nitrocellulose membranes.
The membranes were hybridized with various primary
antibodies (APP 6E10, 1/500, Covance; PS1, 1/1000,
Millipore; APP C-ter, 1/500, Millipore; Actin, 1/2000,
Abcam; GAPDH, 1/1000 Abcam; Total Tau, 1/1000,
Santa Cruz; PSD-95, Invitrogen, 1/2000; Synaptophysin,
Santa Cruz, 1/200; GAD65, Abcam, 1/2000; GLT-1, 1/
1000, Frontier Science; GLAST, 1/1000, Frontier Sci-
ence; NeuN, Millipore, 1/1000). Various secondary anti-
bodies was also used (ECL Anti-rabbit Horseradish
Peroxidase linked, 1/2000, GE Healthcare; ECL Anti-
mouse Horseradish Peroxidase linked, 1/2000, GE
Healthcare; ECL Anti-rat Horseradish Peroxidase linked,
1/2000, GE Healthcare).
Immunohistochemistry and image acquisition
Cryosections were washed with 0.25 % Triton in PBS
and saturated by incubation (0.25 % Triton in PBS/5 %
goat serum). They were then incubated with primary
antibodies (APP C-ter, 1/500, Millipore; NeuN-Biotin, 1/
1000, Millipore; 4G8-Biotin, 1/1000, Covance). Images
were taken with a Nikon Eclipse Ti Microscope or a
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Leica TCS SP8 confocal microscope and analyzed with
ImageJ software (NIH).
Behavioral assessment
Open-field
The apparatus consisted of an open-topped, clear Plexi-
glas box measuring 50 x 50 x 38 cm placed in a room
with controlled dim lighting (25 lux) and constant white
noise at 60 dB. The mice were placed in the center of
the arena and a video recording was made over a period
of five minutes. The behavior of the animals was ana-
lyzed from this video. The arena was divided into a cen-
tral region (20 x 20 cm) and a peripheral region, and the
time spent in the center and periphery of the open field
was measured. The ratio of time spent in the periphery
to that spent in the center was calculated as an index of
emotional behavior.
Ymaze
The apparatus consisted of three identical arms sepa-
rated by 120°. Each arm of the Y maze was 37 cm long,
and 8 cm wide, with 12.5 cm-high opaque walls. Various
extra maze cues were placed on the surrounding walls.
One arm of the Y-maze was blocked and the subject was
allowed to explore the other two arms for 10 min. The
starting position was varied pseudorandomly, between
the three arms. The animal was then returned to its
home cage. Fifteen minutes later, the mouse was placed
in the maze again, this time with all three arms open,
and allowed to explore for an additional five minutes.
The distance traveled and the number of times the
mouse entered each arm were measured both during ini-
tial exposure to the maze and during testing.
Morris water maze
Experiments were performed in a tank 120 cm in diam-
eter and 50 cm deep, filled with opacified water kept at
21 °C and equipped with a platform 10 cm in diameter,
kept submerged 1 cm below the surface of the water.
Visual clues were positioned around the pool, to provide
the mouse with spatial landmarks, and luminosity was
maintained at 350 lux. The mice were initially exposed
to a learning phase, which consisted of daily sessions
(three trials per session) on five consecutive days. The
starting position was varied pseudorandomly, between
the four cardinal points. A mean interval of 15 min was
left between trials. The trial was considered to have
ended when the animal reached the platform. A 60-s
cutoff was used, after which the mice were gently guided
to the platform. Once on the platform, the animals were
allowed to rest for 30 s before being returned to their
cage. Long-term spatial memory was assessed 72 h after
the last training trial (fifth day), in a probe trial in which
the platform was no longer available. Animals were
monitored with ANY-maze video tracking software
(Stoelting Co, Wood Dale, USA).
Ex vivo electrophysiology
Mice were anesthetized with halothane and decapitated.
The brain was rapidly removed from the skull and
placed in chilled (0–3 °C) artificial cerebrospinal fluid
(ACSF) containing 124 mM NaCl, 3.5 mM KCl, 1.5 mM
MgSO4, 2.5 mM CaCl2, 26.2 mM NaHCO3, 1.2 mM
NaH2PO4, 11 mM glucose. Transverse slices (300–400
μm thick) were cut with a vibratome and placed in
ACSF in a holding chamber, at 27 °C, for at least one
hour before recording. Each slice was individually trans-
ferred to a submersion-type recording chamber and
submerged in ACSF continuously superfused and equili-
brated with 95 % O2, 5 % CO2.
The biophysical properties of the tonic current gener-
ated by the activation of extrasynaptic NMDA receptors
with ambient glutamate were evaluated. Whole-cell
patch-clamp recordings of CA1 pyramidal cells were
performed at room temperature, with borosilicate patch
pipettes (5 MΩ) filled with 140 mM CsCH4O3S, 6 mM
CsCl, 2 mM MgCl2, 10 mM HEPES, 1.1 mM EGTA, 5
mM QX-314 5, 4 mM ATP, (pH 7.3; 290 mosm). Trans-
membrane currents were acquired and filtered through
an amplifier (AxoPatch 1-D, Axon Instruments), stored
on a computer and digitized with WinLTP software for
analysis [62]. The tonic current was recorded at a hold-
ing potential of +40 mV, in the presence of TTX (1 μM),
NBQX (10 μM), and bicuculline (10 μM), to isolate the
NMDA component of the holding current (hc). After
the recording of a stable control hc for three to five mi-
nutes, APV (50 μM) was added to the superfusion
medium. The hc fell to a new stable value under the ef-
fect of APV, and the difference between the control hc
and that recorded in the presence of APV determined
the amplitude of the tonic current.
Two kinds of electrically induced long-term potenti-
ation (LTP) were studied: a strong, saturating LTP con-
sisting of 3x100 Hz (3x 100 pulses, 1 s, with 20 s
between pulses), and a weaker stimulation, theta-burst
stimulation (TBS), mimicking the natural stimulation at
the theta frequency from the medial septum to the
hippocampus, consisting of five trains of four 100 Hz
pulses each, separated by 200 ms and delivered at the
test intensity. The sequence was repeated three times,
with an interburst interval of 10s. Testing with a single
pulse was resumed for 60 min (TBS) or 75 min (3x100
Hz), to determine the level of LTP.
Proton magnetic resonance spectroscopy (1H-MRS)
Magnetic Resonance Imaging and Magnetic Resonance
Spectroscopy were performed with a horizontal 11.7 T
scanner (Bruker, Ettlingen, Germany) and a quadrature
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cryoprobe was used for radiofrequency transmission and
reception. A 37.4 μl voxel (7.2 × 2 × 2.6 mm3) was
placed over both hemispheres, such that it contained es-
sentially hippocampal tissue (Fig. 5), and the signal of
this voxel was then averaged over 10 min. T2-weighted
images were acquired with a 2D TurboRARE sequence
(80 × 80 μm2 in-plane resolution, and 300 μm slice
thickness) and manually segmented to measure hippo-
campal volume. 1H-MRS acquisitions were performed
with a LASER sequence, with echo time (TE)/repetition
time (TR) = 20/5000 ms and a 10 kHz bandwidth for
the hyperbolic secant pulses. LCModel was used to de-
termine metabolite concentrations. The macromolecule
(MM) spectrum of a control mouse was determined by
metabolite nulling and included in the base set for
LCModel. The following metabolites were systematically
quantified (Cramér-Rao lower limits <5 % in all experi-
ments): total choline (glycerophosphocholine + phos-
phocholine + choline, tCho), total creatine (creatine +
phosphocreatine, tCr), glutamate (Glu), glutamine (Gln),
myo-inositol (Ins), N-acetyl-aspartate + N-acetyl-
aspartyl-glutamate (NAA + NAAG, tNAA), taurine (T)
and γ-aminobutyric acid (GABA). Metabolite concentra-
tions were normalized with respect to 8 mM tCr.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analyses
were performed with GraphPad Prism (GraphPad Soft-
ware, La Jolla, CA, USA) or Statistica (StatSoft, Inc.,
Tulsa, OK, USA) software. One-way ANOVA and
Tukey’s post-hoc test were used to determine the signifi-
cance of differences between groups. Student’s t test was
used when only two groups were analyzed (AAV-PS1 vs
AAV-APP/PS1), except for tonic glutamatergic current
recording, for which Chi2 tests were used. Two-way
ANOVA with repeated measure using Group and Me-
tabolite as effect factors, was used for NMR spectros-
copy analysis.
Additional files
Additional file 1: Figure S1. APP is processed in sporadic AD cases.
Human samples were obtained from late-onset AD cases (Braak 6, Thal 5)
and age-matched controls (n = 5 per group). The hippocampus was the
studied structure. (A) Western blot analysis of NeuN. (B) Densitometric
analyses of western blots showing the expression of human APP in the
hippocampus of human controls and AD cases (n = 5 per group). Bars
represent means ± SEM, and data were normalized with respect to
GAPDH. Statistical analyses were performed with Student’s t-test: **p <
0.01. (C) Densitometric analyses of A, showing the expression of NeuN in
the hippocampus of human controls and AD cases (n = 5 per group).
Bars represent means ± SEM, and data were normalized with respect to
GAPDH. Statistical analyses were performed with Student’s t-test: *p <
0.05. (D) Representation of the APP/NeuN ratio following densitometric
analyses of the corresponding western blots (n = 5 per group). Note that
APP seems to be processed in sporadic AD cases. Bars represent means ±
SEM and data were normalized with respect to GAPDH. Statistical
analyses were performed with Student’s t-test: *p < 0.05. (PNG 325 kb)
Additional file 2: Figure S2. AAV-PS1 and AAV-APP mice do not
exhibit neuronal defects in terms of PSD-95, GLT-1 and tonic
glutamatergic current. C57Bl/6 J mice (all males) were injected at
8 weeks of age either with AAV-CAG-PS1M146L (AAV-PS1 mice) or
AAV-CAG-APPSL (AAV-APP mice). Mice were killed three months later
for analyses. (A) Western blot of PSD-95 and GLT-1 (n = 3-4 per
group). (B) Densitometric analyses of the antibody immunoreactivities
shown in panel A. (C) Tonic glutamatergic current recorded at a
holding potential of +40 mV by the whole-cell patch-clamping of
CA1 pyramidal cells. No significant difference in tonic glutamatergic
current intensity was observed between the AAV-PS1 and AAV-APP
groups (whole cell patch-clamp of CA1 pyramidal cells, n = 11/group
from n = 10 mice per group). (PNG 447 kb)
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